Who got booted to the May meet?

The PBAC has revealed the 16 medicines which companies hoped would be considered for reimbursement in March but were controversially booted to an additional meeting in May due to evaluation capacity constraints.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here